达格列净治疗2型糖尿病合并心力衰竭的效果分析  

Effect of dapagliflozin on heart failure in type 2 diabetes mellitus

作　　者：乔琛琛 李科民[1] 刘安全[1] QIAO Chenchen;LI Kemin;LIU Anquan(Department of Cardiology,the First People’s Hospital of Bengbu,Bengbu 233000,China)

机构地区：[1]安徽省蚌埠市第一人民医院心血管内科,蚌埠233000

出　　处：《上海医药》2021年第21期28-31,58,共5页Shanghai Medical & Pharmaceutical Journal

摘　　要：目的:评价达格列净在2型糖尿病合并心力衰竭患者中应用的临床效果。方法:选取152例2型糖尿病合并心力衰竭患者作为研究对象,分成对照组和观察组各76例,对照组患者行常规药物治疗,观察组选择常规药物加达格列净治疗,比较两组患者6个月后生化指标及心功能指标情况。结果:用药6个月与用药前相比,观察组的体质量等心血管危险因素及左心室舒张末期内径(LVEDD)、N末端B型利钠肽(NT-proBNP)水平均降低且低于对照组(P<0.05),而左心室射血分数(LVEF)水平则上升。结论:对于2型糖尿病合并心力衰竭患者,达格列净除降糖作用外,能够显著改善患者心功能,值得临床试用。Objective:To analyze the effect of dapagliflozin on heart failure in patients with type 2 diabetes mellitus(T2DM).Methods:Clinical data from 152 cases of T2DM patients with heart failure were collected and the patients were divided into a control group(treated with conventional medication)and an observation group(treated with conventional medication plus dapagliflozin)with 76 cases each.The biochemical indexes and cardiac function indexes were collected and analyzed 6 months after treatment.Results:The levels of cardiovascular risk factors such as body mass and the left ventricular end-diastolic dimension(LVEDD)and the N-terminal-pro-B-type natriuretic peptide(NT-proBNP)were all decreased while the left ventricular ejection fraction(LVEF)levels were increased in the observation group at 6 months after treatment compared with those before treatment(P<0.05).Conclusion:Dapagliflozin is a valuable option for the management of patients with T2DM and heart failure because it can improve heart failure besides hypoglycemia effect and is worthy of clinical trial.

关 键 词：心力衰竭 2型糖尿病 达格列净 

分 类 号：R977.15[医药卫生—药品] R587.1[医药卫生—药学]